@misc{ReichetzederHocher2017,
  author    = {Reichetzeder, Christoph and Hocher, Berthold},
  title     = {DPP4 inhibition prevents AKI},
  series = {Oncotarget},
  volume    = {8},
  journal   = {Oncotarget},
  publisher = {Impact Journals LLC},
  address   = {Orchard Park},
  issn      = {1949-2553},
  doi       = {10.18632/oncotarget.20212},
  pages     = {64655 -- 64656},
  year      = {2017},
  language  = {en}
}
@misc{PischonRadbruchOstrowskietal.2017,
  author    = {Pischon, Hannah and Radbruch, Moritz and Ostrowski, Anja and Schumacher, Fabian and Hoenzke, Stefan and Kleuser, Burkhard and Hedtrich, Sarah and Fluhr, Joachim W. and Gruber, Achim D. and Mundhenk, Lars},
  title     = {How Effective Is Tacrolimus in the Imiquimod},
  series = {The journal of investigative dermatology},
  volume    = {138},
  journal   = {The journal of investigative dermatology},
  number    = {2},
  publisher = {Elsevier},
  address   = {New York},
  issn      = {0022-202X},
  doi       = {10.1016/j.jid.2017.09.019},
  pages     = {455 -- 458},
  year      = {2017},
  language  = {en}
}
@misc{Kleuser2017,
  author    = {Kleuser, Burkhard},
  title     = {Medikamentennebenwirkungen auf Haut und Schleimhaut - allergische oder pharmakologisch erkl{\"a}rbare Reaktionen},
  series = {Allergologie},
  volume    = {40},
  journal   = {Allergologie},
  number    = {10},
  publisher = {Dustri-Verlag},
  address   = {Deisenhofen-M{\"u}nchen},
  issn      = {0344-5062},
  pages     = {420 -- 421},
  year      = {2017},
  language  = {de}
}
@misc{DoegeSchumacherBalzusetal.2017,
  author    = {D{\"o}ge, Nadine and Schumacher, Fabian and Balzus, Benjamin and Colombo, Miriam and Hadam, Sabrina and Rancan, Fiorenza and Blume-Peytavi, Ulrike and Kleuser, Burkhard and Bodmeier, Roland and Vogt, Annika},
  title     = {Particle- based formulations and controlled skin barrier disruption have a signifi cant impact on the delivery and penetration kinetics of dexamethasone as assessed in an ex vivo microdialysis},
  series = {Journal der Deutschen Dermatologischen Gesellschaft},
  volume    = {15},
  journal   = {Journal der Deutschen Dermatologischen Gesellschaft},
  publisher = {Wiley},
  address   = {Berlin},
  issn      = {1610-0379},
  pages     = {182 -- 182},
  year      = {2017},
  abstract  = {Preclinical assessment of penetration not only in intact, but also in barrier-disrupted skin is important to explore the surplus value of novel drug delivery systems, which can be specifically designed for diseased skin. Here, we characterized physical and chemical barrier disruption protocols for short-term ex vivo skin cultures with regard to structural integrity, physiological and biological parameters. Further, we compared the penetration of dexamethasone (Dex) in different nanoparticle-based formulations in stratum corneum, epidermis and dermis extracts of intact vs. barrier-disrupted skin as well as by dermal microdialysis at 6, 12 and 24 hours after topical application. Dex was quantified by liquid-chromatography - tandem-mass spectrometry (LC-MS/MS). Simultaneously, we investigated the Dex efficacy by interleukin (IL) analysis. Tape-stripping (TS) and 4 hours sodium lauryl sulfate 5 \% (SLS) exposure were identified as highly effective barrier disruption methods assessed by reproducible transepidermal water loss (TEWL) changes and IL-6/8 increase which was more pronounced in SLS-treated skin. The barrier state has also a significant impact on the Dex penetration kinetics: for all formulations, TS highly increased dermal Dex concentration despite the fact that nanocrystals quickly and effectively penetrated both, intact and barrier-disrupted skin reaching significantly higher dermal Dex concentration after 6 hours compared to Dex cream. The surplus value of encapsulation in ethyl cellulose nanocarriers could mostly be observed when applied on intact skin, in general showing a delayed Dex penetration. Estimation of cytokines was limited due to the trauma caused by probe insertion. In summary, ex vivo human skin is a highly interesting short-term preclinical model for the analysis of penetration and efficacy of novel drug delivery systems.},
  language  = {en}
}
@misc{HocherTsuprykov2017,
  author    = {Hocher, Berthold and Tsuprykov, Oleg},
  title     = {Renoprotective effects of GLP1R agonists and SGLT2 inhibitors},
  series = {Nature reviews nephroloy},
  volume    = {13},
  journal   = {Nature reviews nephroloy},
  publisher = {Nature Publ. Group},
  address   = {New York},
  issn      = {1759-5061},
  doi       = {10.1038/nrneph.2017.140},
  pages     = {728 -- 729},
  year      = {2017},
  abstract  = {New data from the LEADER trial show that the glucagon-like peptide 1 receptor agonist liraglutide protects against diabetic nephropathy in patients with type 2 diabetes mellitus. The renoprotective efficacy of liraglutide is not, however, as great as that reported for the sodium-glucose cotransporter 2 inhibitor emplagiflozin in the EMPA-REG OUTCOME trial.},
  language  = {en}
}
@misc{HalibasicFuerstHeidenetal.2017,
  author    = {Halibasic, Emina and Fuerst, Elisabeth and Heiden, Denis and Japtok, Lukasz and Diesner, Susanne C. and Hillebrand, P. and Trauner, Michael and Kleuser, Burkhard and Kazemi-Shirazi, Lili and Untersmayr, Eva},
  title     = {Significantly reduced plasma levels of the bioactive sphingolipid S1P in lung transplanted cystic fibrosis patients are associated with gastrointestinal symptoms},
  series = {Allergy},
  volume    = {72},
  journal   = {Allergy},
  number    = {S103},
  publisher = {Wiley},
  address   = {Hoboken},
  issn      = {0105-4538},
  pages     = {195 -- 195},
  year      = {2017},
  language  = {en}
}